ERBB2 and breast cancer: In fact, several authors have reported the considerable therapeutic benefits of TZ treatment in HER2-positive BC despite its association with cardiotoxicity and a critical need to elucidate the molecular mechanisms of this cardiotoxicity, e.g., [18].